INVESTMENT INSIGHTS - Innoviva Incorporated

START - $22.33 | FINISH - $25.90

1. HORIZON: 0 - 3 months (Short-Term)

2. FROM: 5 June 2026 | UNTIL: 4 September 2026

3. MANAGEMENT ASSESSMENT: 16% growth

4. RECOMMENDATION: BUY

5. PROJECTION BASED ON: R10 000 

TRADING PLAN

●      Potential Entry: Initiate a position once the share price closes above $22.33, with the 200-day simple moving average (SMA) acting as medium-term resistance.

●      Risk Management: The stop-loss is set at $21, just below the 200-day SMA. From the $22.33 entry, this represents a ~6% drawdown and defines the maximum acceptable loss on the trade. 

●      Profit Target: The primary target is $25.90,  a ~16% gain from the entry level.

WHY THESE SHARES HAVE POTENTIAL FOR PROFIT

●      ZEVTERA has barely started, and that's the opportunity

Think of ZEVTERA as the new product that just got onto store shelves but hasn't been stocked by most major retailers yet. Before a hospital can prescribe any new drug, it has to go through an internal approval committee. ZEVTERA only launched in mid-2025 and is still going through that process, which is why it earned just $438 000 in sales in Q1 2026. Once hospitals formally approve it, sales should accelerate sharply. Innoviva's broader drug sales division is already growing at 29% year-over-year, and the company is guiding for $150 million or more in drug sales for 2026. ZEVTERA's contribution to that number is still near zero, meaning the upside is almost entirely ahead of us. 

●      A new drug for a problem with no modern solution

Gonorrhoea is becoming increasingly resistant to the antibiotics doctors have relied on for decades. The FDA approved Innoviva's NUZOLVENCE in December 2025 as one of the first new single-dose oral treatments for gonorrhoea in nearly 20 years. With roughly 648 000 cases reported in the US in 2022 alone and resistance rising, there is real demand for a new option. Innoviva plans to bring NUZOLVENCE to market in the second half of 2026. This is a completely new source of income the company doesn't have today. 

●      A royalty cheque that keeps coming, and management is buying its own stock

Every year, GSK sells millions of Breo and ANORO inhalers to people managing asthma and lung disease. Innoviva holds the royalty rights to those products, which paid out roughly $250 million in 2025, money that flows in whether Innoviva does anything or not. That steady income funds the new drug launches and keeps the balance sheet strong, with $603 million in cash as of March 2026. On top of that, Innoviva's own management launched a $125 million programme to buy back some company shares, a clear signal they believe the stock is undervalued. The overall numbers back this up; in Q1 2026, the company swung from a $0.74 loss per share to a profit of $2.22 per share compared to the same period last year. 

TECHNICAL INDICATORS

●      Trading Above the 200-Day SMA: The share price is currently holding above the 200-day simple moving average, the long-term trend indicator that separates a bullish market structure from a bearish one. Institutional investors use this level as a key benchmark, and the fact that Arista is trading above it confirms longer-term buyers remain in control. Any dip toward this level is likely to attract renewed buying interest, providing a solid floor for the trade. 

●      MACD Bullish Configuration: The moving average convergence divergence (MACD) indicator is showing a bullish setup, with the MACD line positioned above the signal line. This momentum signal confirms that buying pressure is reasserting itself after a period of consolidation. Taken together with the price holding above the 200-day SMA and the post-correction base formation, the confluence of signals presents a technically constructive setup that aligns with the strong fundamental outlook.

RISKS

The royalty income won't last forever

Innoviva's GSK royalties are reliable today, but won't grow, and will eventually shrink as those inhaler products face generic competition. The company's future depends on ZEVTERA and NUZOLVENCE picking up the slack before that happens. 

ZEVTERA could take longer than expected to generate real sales

Getting a new drug onto hospital prescription lists is slow. Management confirmed in March 2026 that ZEVTERA is still early in that approval process. If hospitals are slow to adopt it, the company's $150 million drug sales target for 2026 may be missed. 

NUZOLVENCE has a bigger rival and no launch plan yet

GSK, one of the world's largest pharmaceutical companies, had its own gonorrhoea drug approved one day before NUZOLVENCE, and it has far more salespeople and hospital relationships than Innoviva. Innoviva also hasn't confirmed whether it will launch NUZOLVENCE on its own or with a partner yet, which adds uncertainty. A weak or delayed launch could mean this new drug contributes very little revenue in the near term. 

SOURCES 

●      Innoviva Reports First Quarter 2026 Financial Results

●      Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference

●      U.S. FDA Approves NUZOLVENCE (zoliflodacin) — investor.inva.com

●      FDA Endorses 2nd New Gonorrhea Treatment, Clearing Way for NUZOLVENCE — FiercePharma

●      Innoviva (INVA) Analyst Price Targets — StockAnalysis

●      Innoviva Form 10-Q Q1 FY2026 — SEC EDGAR

●      ZEVTERA Launches Commercially in U.S. — ContagionLive

Disclaimer:
*Any opinions, views, analysis, or other information provided in this article is provided by BROKSTOCK SA trading as BROKSTOCK as general market commentary and should not be viewed as advice according to the FAIS Act of 2002. BROKSTOCK SA does not warrant the correctness, accuracy, timeliness, reliability, or completeness of any information provided by third parties. You must rely upon your judgement in all aspects of your investment decisions, and all decisions are made at your own risk. BROKSTOCK SA and any of its employees shall not be responsible for and will not accept any liability for any direct or indirect loss, including, without limitation, any loss of profit which may arise directly or indirectly from the use of the market commentary. The content contained within the article is subject to change at any time without notice. BROKSTOCK SA is an authorised financial services provider - FSP No. 51404. T&Cs and Disclaimers are applicable: https://brokstock.co.za/
** This article was prepared by BROKSTOCK analyst Maboko Seabi